Study for NTRK fusion cancers taking larotrectinib
Treatments studied
Part of Cancer clinical trials.
This trial is for people with advanced or returning solid tumors that have specific gene changes called NTRK gene fusions. It looks at patients who are already being treated with larotrectinib as part of normal care, to understand this treatment in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced or recurring solid tumor that has an NTRK gene fusion
- You are currently being treated with larotrectinib, or your doctor plans to start it
- You will receive larotrectinib under routine clinical practice (standard care)
- You are not participating in another investigational program that uses extra study treatments outside routine care
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with cancers that have an NTRK gene fusion to learn how safe and effective larotrectinib is during everyday treatment. It may help confirm whether this medicine works well in real-world patients and side effects stay manageable.
This trial studies larotrectinib, a targeted medicine, in people with solid tumors that have extra copies (amplification) of the NTRK1, NTRK2, or NTRK3 gene. It’s for cancers that have already been treated with standard options or where standard options are unlikely to help.
This trial tests a new daily pill (CG001419) for people with advanced solid tumors that have specific changes in the NTRK gene or TRK protein. The study aims to see if the drug is safe and effective, especially in those whose cancers have not responded to other treatments.
This Phase 2 trial tests larotrectinib (a targeted medicine) to help radioactive iodine (RAI) work better in people with differentiated thyroid cancer that has an NTRK gene fusion. It may improve how much thyroid cancer the RAI can reach and shrink.
This trial tests larotrectinib, a targeted cancer medicine, in children and teens with newly diagnosed high-grade brain glioma that has an NTRK fusion. It may help shrink or control tumors by targeting a specific genetic change in the cancer.
This Phase 1/2 study tests ICP-723, a medicine designed to treat cancers that have an NTRK gene fusion. It may help shrink tumors in people whose cancer test shows this specific genetic change and who haven’t taken an NTRK inhibitor before.
Hear when a new Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.